Edit

Treo Ventures

https://treovp.com

Last activity: 23.10.2024

Probably Closed

Invests in categories: MedTechTechnologyHardwareHealthTechProductWearablesDevelopmentAgencyMarketHuman

News

Portfolio

Persons

Mentions

Location: United States, California, Santa Clara

Employees: 1-10

Investment Type: Venture Capital

Investment Stage: Series C

Portfolio 8

Date	Name	Website	Total Raised	Location
08.07.2021	Neuspera M...	neuspera.com	$140M	United Sta...
-	ShiraTroni...	shiratronics.com	$102M	United Sta...
-	Noctrix He...	noctrixhealth.com	$57M	United Sta...
-	BAROSTIM T...	cvrx.com	$265.6M	United Sta...
-	Hyalex	hyalex.com	$49M	United Sta...
-	NeoChord	neochord.com	$97.6M	United Sta...
-	NuXcel	nuxcel.com	-	-
-	Intuity Me...	presspogo.com	$261M	United Sta...

Persons 4

Date	First Name	Last Name	Title	LinkedIn	Twitter	Email	Location
-	Dave	Shanahan, ...	Venture Pa...	linkedin.c...	-	-	-
-	Mudit	K. Jain, P...	Founder an...	linkedin.c...	-	-	-
-	Tracy	Pappas	General Pa...	linkedin.c...	-	-	-
-	Brad	H. Vale, P...	Founder an...	linkedin.c...	-	-	-

News 53

Date	Title	Description
09.10.2024	ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine	-
07.10.2024	InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance	-
03.10.2024	Noctrix Health Announces Favorable Inclusion of Nidra Tonic Motor Activation (TOMAC) Therapy in New American Academy of Sleep Medicine (AASM) Clinical Practice Guidelines for Restless Legs Syndrome (R...	-
12.09.2024	CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim	-
12.09.2024	Neuspera Medical, Inc. Welcomes Bunty Banerjee as Its First Chief Operating Officer	-
19.08.2024	Noctrix Health Announces New CMS Reimbursement Codes for Payment for Nidra Tonic Motor Activation (TOMAC) Therapy for Restless Legs Syndrome (RLS)	-
02.08.2024	CVRx Announces Increased Inpatient Payment for Barostim Procedure	-
29.07.2024	CVRx Reports Second Quarter 2024 Financial and Operating Results	-
26.07.2024	Neuspera Medical, Inc. Reaches Significant Milestone: Final Patient has Completed Primary Endpoint Visit in the SANS-UUI Pivotal Clinical Trial	-
16.07.2024	ShiraTronics Unveils Data on their Neurostimulation System for Chronic Migraine	-
15.07.2024	Neuspera Medical Raises $23 Million in Series D Financing	-
30.04.2024	CVRx Reports First Quarter 2024 Financial and Operating Results	-
22.04.2024	iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors	-
22.04.2024	Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System	-
22.02.2024	NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation	-
06.02.2024	ShiraTronics Completes Australian Pilot Study Enrollment; Prepares for Pivotal Clinical Study	-
31.01.2024	CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer	-
25.01.2024	CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	-
26.12.2023	CVRx receives FDA approval for expanded labeling of Barostim	-
19.12.2023	ShiraTronics Announces Landmark Achievement: World’s First Implant of its Innovative Chronic Migraine System	-
06.12.2023	Neuspera Medical, Inc. Completes Patient Enrollment and Implants for the SANS-UUI Pivotal Clinical Trial	-
29.11.2023	ShiraTronics Announces Groundbreaking Milestone: World’s First Trial Phase Procedures for their Chronic Migraine Therapy System in Australian Pilot Study	-
26.10.2023	CVRx Reports Third Quarter 2023 Financial and Operating Results	-
26.10.2023	CMS Increases Outpatient Payment for Barostim Procedure	-
26.07.2023	Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Synd...	-
25.07.2023	CVRx Reports Second Quarter 2023 Financial and Operating Results	-
22.06.2023	CVRx Set to Join Russell 2000 & 3000 Indexes	-
09.05.2023	Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy	-
27.04.2023	CVRx Reports First Quarter 2023 Financial and Operating Results	-
18.04.2023	Neuspera Medical® Announces FDA Clearance of its System for Peripheral Nerve Stimulation	-
06.03.2023	Neuspera Hires Courtney Lane to Lead Clinical and Regulatory Affairs	-
26.01.2023	CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results	-
07.11.2022	Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes	-
19.10.2022	NeoChord Announces Positive 1-year Follow-Up Data with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor	-
13.10.2022	Neuspera Medical® announces first successful implant of the Nuvella™ System in the second phase of its sans-UUI IDE Clinical Trial	-
15.09.2022	ShiraTronics, Inc. Welcomes New CEO	-
14.06.2022	Neuspera Medical® Announces Second Phase of SANS-UUI IDE Clinical Trial with the Nuvella™ System	-
09.06.2022	Neuspera Medical® Appoints Steffen Hovard as CEO	-
28.02.2022	NeoChord’s Transfemoral Mitral Valve Repair System Wins CRT 2022 Best Innovation Competition	-
06.07.2021	Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx	-
29.06.2021	CVRx, Inc. Announces Upsized Pricing of Initial Public Offering	-
10.04.2021	NeoChord Announces Successful Completion of First in Human Procedure with its NeoChord NeXuS Transcatheter Mitral Chordal Repair Technology	-
08.02.2021	ShiraTronics, Inc. Receives FDA Breakthrough Device Designation for Chronic Migraine Neurostimulation	-
12.01.2021	Strategic Healthcare Investment Partners Closes $128M Debut Medical Devices and Digital Health Venture Fund and Rebrands Itself as Treo Ventures.	-
11.01.2021	Noctrix Health, Inc. Completes $17 Million Series B Financing.	-
05.01.2021	CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing.	-
03.12.2020	CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status.	-
07.07.2020	CVRx® Raises $50 Million in New Equity Financing.	-
26.03.2020	ShiraTronics, Inc. Completes $3 Million Additional Series A Financing.	-
25.10.2019	ShiraTronics, Inc. Completes $33M Million Series A Financing.	-
16.08.2019	CVRx® Receives FDA Approval for World’s First Heart Failure Neuromodulation Device.	-
02.05.2019	Hyalex Orthopaedics, synthetic cartilage company, adds new funding; expanding Series A total to $33MM.	-
02.05.2019	NeoChord Raises Additional Financing to Drive Catheter‐based Program Development, Bringing Total Series D Funding to over $32 Million.	-

Mentions in press and media 1

Date	Title	Description
06.07.2021	Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx® (NSDQ: CVRX)	SANTA CLARA, Calif. and DUBLIN, July 6, 2021 /PRNewswire/ -- Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market. Treo led the pre-IPO round in July 2020...

Treo Ventures

Portfolio 8

Persons 4

News 53

Mentions in press and media 1

Reviews 0